Macro: Sandcastle economics
Invest wisely in Q3 2024: Discover SaxoStrats' insights on navigating a stable yet fragile global economy.
Chief Investment Strategist
Chinese equities traded in Hong Kong are up 20% from their lows earlier this month as the Chinese government pulled out the stimulus bazooka including support for the stock market. The People’s Bank of China has also recently lowered key benchmark rates and other measures have been implemented to shore the distress in the Chinese property sector. In the short-term, tactical traders and momentum chasing investors are bidding up Chinese equities, but for the long-term investor the fundamental question is different. Is this enough to break the downward spiral from its balance sheet recession that China is facing.
The excessive private sector debt in China means that lower interest rates may not solve anything like the developed world learned in the aftermath of the Great Financial Crisis. For China the problem is even bigger. China’s pension age is 60 and the dependency ratio was 46.6% in 2022 and is expected to surge in the years to come. That means a larger part of the population will live from passive income and thus lower interest rates will both suppress passive income for the elderly non-working population, but for the working population higher savings rate is needed to generate a meaningful passive income in the future. That could lower consumption in the economy and make it more difficult to get out of the balance sheet recession.
Some of the best performing Chinese stocks in the Hang Seng Index, the leading Hong Kong benchmark index, are Meituan and JD.com reflecting increased expectations for higher consumer spending. In Europe, we have seen similar reaction in luxury stocks such as LVMH.
Micron Technology reported a better-than-expected outlook on Wednesday due to the boom in AI. The DRAM memory chip market is booming with tight supply driving prices higher and the chipmaker expects unit growth again in the global PC market in 2025. Micron Technology has always had a strong correlation to the global economic growth cycle. An upbeat outlook from Micron is a positive macro indicator.
On Wednesday, I did a presentation on the global health care sector for some our clients. The other presenters were Claus Henrik Johansen, Chief Investment Officer, at Global Health Invest which is a new mutual fund expected to IPO 1 November 2024 on Nasdaq Copenhagen. Claus comes with 20 years of experience in the health care sector as a senior portfolio manager at Danske Bank Asset Management. The last presenter was Henning Langberg giving insights into how technology, including AI, is already being implemented in the Danish health care sector and what the potential is for productivity gains in the future.
I could write for an hour of all things I learned, but some of the key take-ways were the following:
One of the key charts that I showed was the one below. It shows the revenue per share cumulative growth over the past 10 years. The key insight here is the remarkable consistency in growth and its extremely low sensitivity to the economic cycle. In other words, the global health care sector is both a growth and defensive sector at the same time, which is a very unique characteristic not shared by many other sectors or industries.
Previous weekly equity market updates
Disclaimer
The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website. This content is not intended to and does not change or expand on the execution-only service. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.
Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-gb/legal/disclaimer/saxo-disclaimer)